Several analysts have recently updated their ratings and price targets for Bristol-Myers Squibb (NYSE: BMY):

  • 9/28/2017 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $63.67 price target on the stock.
  • 9/27/2017 – Bristol-Myers Squibb was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $66.50 price target on the stock.
  • 9/27/2017 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $72.00 price target on the stock.
  • 9/19/2017 – Bristol-Myers Squibb had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $65.00 price target on the stock.
  • 9/12/2017 – Bristol-Myers Squibb was downgraded by analysts at Hilliard Lyons from a “long-term buy” rating to a “neutral” rating. They now have a $65.00 price target on the stock.
  • 9/11/2017 – Bristol-Myers Squibb had its price target raised by analysts at Jefferies Group LLC from $66.00 to $72.00. They now have a “buy” rating on the stock.
  • 9/8/2017 – Bristol-Myers Squibb had its “hold” rating reaffirmed by analysts at Credit Suisse Group.
  • 9/7/2017 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $65.00 price target on the stock, up previously from $62.00.
  • 9/7/2017 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $64.20 price target on the stock.
  • 9/4/2017 – Bristol-Myers Squibb had its “sell” rating reaffirmed by analysts at BMO Capital Markets. They now have a $49.00 price target on the stock.
  • 8/24/2017 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $66.00 price target on the stock, up previously from $63.00.
  • 8/22/2017 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $64.20 price target on the stock.
  • 8/17/2017 – Bristol-Myers Squibb was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $64.08 price target on the stock.
  • 8/16/2017 – Bristol-Myers Squibb was given a new $58.00 price target on by analysts at Credit Suisse Group. They now have a “hold” rating on the stock.
  • 8/14/2017 – Bristol-Myers Squibb was given a new $65.00 price target on by analysts at Cowen and Company. They now have a “hold” rating on the stock.
  • 8/12/2017 – Bristol-Myers Squibb was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/10/2017 – Bristol-Myers Squibb was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $64.08 price target on the stock.
  • 8/9/2017 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $63.81 price target on the stock.
  • 8/9/2017 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $63.00 price target on the stock.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 64.29 on Wednesday. The company has a 50-day moving average price of $60.96 and a 200 day moving average price of $56.48. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $64.79. The firm has a market capitalization of $105.43 billion, a price-to-earnings ratio of 23.48 and a beta of 1.19.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. Bristol-Myers Squibb’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.69 earnings per share. On average, equities research analysts predict that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.43%. Bristol-Myers Squibb’s payout ratio is presently 56.73%.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.